Potentiation by bovine serum albumin(BSA) of endothelium-dependent vasodilator response to acetyl glyceryl ether phosphorylcholine (AGEPC).
- 1 January 1987
- journal article
- research article
- Published by Pharmaceutical Society of Japan in Journal of Pharmacobio-Dynamics
- Vol. 10 (5) , 220-228
- https://doi.org/10.1248/bpb1978.10.220
Abstract
Endothelium-dependent vasodilator responses of isolated rat aortic strips precontracted with norepinephrine to acetyl glyceryl ether phosphorylcholine (AGEPC) were compared in the presence and absence of bovine serum albumin (BSA). In the absence of BSA, AGEPC produced endothelium-dependent relaxation at concentrations higher than 10-6 M, which was considered to be non-specific because similar relaxations were produced by other phospholipids (e.g., lysolecithin) at the same concentration range. This non-specific relaxation was suggested to be caused by changes in membrane fluidity of endothelial cells, singe high concentrations of AGEPC and other phospholipids were found to produce structural changes in endothelial cells by phase contrast and electron microscopic studies; structural changes were never observed after the application of acetylcholine (ACh). In the presence of BSA (2.5 mg/ml), AGEPC caused endothelium-dependent relaxation at concentrations as low a 10-9 M; however, relaxations by ACh and lysolecithin were not augmented by the presence of BSA. CV-3988 (10-5 M), a specific antagonist of AGEPC, inhibited the relaxations by AGEPC in the presence of BSA. From these results, it is suggested that, in the presence of BSA, AGEPC may produce endothelium-dependent relaxation in a specific manner, which is different from the non-specific relaxations observed in the absence of BSA.This publication has 11 references indexed in Scilit:
- Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the plateletBiochemical Pharmacology, 1985
- Platelet activating factor analogues: Lack of correlation between their activities to produce hypotension and endothelium-mediated vasodilation.Journal of Pharmacobio-Dynamics, 1985
- Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholineEuropean Journal of Pharmacology, 1984
- Specific receptor sites for 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranesBiochemistry, 1983
- Aortic vascular and atrial responses to (±)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholineBritish Journal of Pharmacology, 1983
- CV-3988 - A specific antagonist of platelet activating factor (PAF)Life Sciences, 1983
- Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs.Journal of Pharmacobio-Dynamics, 1983
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980
- Studies on isolated smooth muscle cells. I. Continuous observation of contraction of single smooth muscle cells isolated from Vas deferens of guinea pig.CHEMICAL & PHARMACEUTICAL BULLETIN, 1977
- Effect of Albumin and Methylated Albumin on the Glucose Permeability of Lipid MembranesThe Journal of Biochemistry, 1976